Accrington late night bar back on market after sale falls through
A bar which has been closed since pre-pandemic has gone back on the market after its sale fell through. ibar in Accrington closed for renovation work in 2020 but never reopened after various lockdown measures which caused huge difficulties in the hospitality industry.
The Birmingham firm which owns the leasehold of the club, Hawthorn, explained last year that it did not plan to reopen the venue, but instead was intending to invest in the adjoining Warner Arms pub for which it is also responsible. The sale process had been progressing but estate agent Fleurets has relisted the property "due to abortive negotiations".
The town centre club, on Warner Street, is part of a two-storey property which has an open plan ground floor in excess of 1,100 sq ft. The first floor is used for storage but currently lies in a "semi-derelict" state and is described as having potential for redevelopment. The building is Grade II listed and Fleurets suggest developers looking for an alternative use would best consider retail or commercial use.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Meredith Kercher's parents died within four months of each other in 2020THE parents of Meredith Kercher died within four months of each other, her hearbroken family have revealed. It comes just days after pictures emerged of former suspects Amanda Knox and ex-lover Raf…
Lire la suite »
Sackboy: A Big Adventure has weak start on PCSackboy: A Big Adventure hasn't had a big start on Steam. Originally released on PlayStation consoles in November 2020 …
Lire la suite »
‘It Wasn't Worth It': Threats Against Election Workers Have Some Leaving the JobPatty McKerley had dealt with election observers before. But she said nothing could have prepared her for the encounter she had last November when an armed election observer walked into the Manchester, N.H., polling location where she was the moderator.
Lire la suite »
'I looked old and drained, now I'm living my best life after my divorce'Emma Sheppard, 42 has completely transformed herself after splitting from her husband of 18 years in 2020
Lire la suite »
Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19 - TrialsAim To inform the oversight of future clinical trials during a pandemic, we summarise the experiences of the Data Monitoring Committee (DMC) for the Randomised Evaluation of COVID therapy trial (RECOVERY), a large-scale randomised adaptive platform clinical trial of treatments for hospitalised patients with COVID-19. Methods and findings During the first 24 months of the trial (March 2020 to February 2022), the DMC oversaw accumulating data for 14 treatments in adults (plus 10 in children) involving | 45,000 randomised patients. Five trial aspects key for the DMC in performing its role were: a large committee of members, including some with extensive DMC experience and others who had broad clinical expertise; clear strategic planning, communication, and responsiveness by the trial principal investigators; data collection and analysis systems able to cope with phases of very rapid recruitment and link to electronic health records; an ability to work constructively with regulators (and other DMCs) to address emerging concerns without the need to release unblinded mortality results; and the use of videoconferencing systems that enabled national and international members to meet at short notice and from home during the pandemic when physical meetings were impossible. Challenges included that the first four treatments introduced were effectively ‘competing’ for patients (increasing pressure to make rapid decisions on each one); balancing the global health imperative to report on findings with the need to maintain confidentiality until the results were sufficiently certain to appropriately inform treatment decisions; and reliably assessing safety, especially for newer agents introduced after the initial wave and in the small numbers of pregnant women and children included. We present a series of case vignettes to illustrate some of the issues and the DMC decision-making related to hydroxychloroquine, dexamethasone, casirivimab + imdevimab, and tocilizumab. Conclusions REC
Lire la suite »